Pulse Biosciences, Inc. PLSE
52.20 USD -0.70 (-1.32%)
At closeNov 3, 2026, 4:00 PM EST
52.20 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
51.64 Day range 55.20
12.56 52-week range 58.90
- YTD
- +280.19%
- 1 year
- +210.90%
- Market cap
- 3.72B
- Revenue (ttm)
- 1.19M
- EPS (ttm)
- -1.18
- Shares out
- 71.32M
- Forward P/E
- -44.62
- YTD return
- +280.19%
- 1-year return
- +210.90%
- Volume
- 386.07K
- Avg volume
- 501.83K
- Open
- 53.42
- Previous close
- 52.90
- Day's range
- 51.64 – 55.20
- 52-week range
- 12.56 – 58.90
- Beta
- 1.64
- Price target
- 62.33 (+19.4%)
- Earnings date
- Nov 5, 2026
2Y +36.90 (+242.92%)
Key statistics
- Enterprise value
- 3.68B
- PEG ratio
- 0.00
- Price / sales
- 3141.81
- Price / book
- 37.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -34.29M
- Total cash
- 101.62M
- Total debt
- 6.77M
- Return on equity
- -78.49%
- Short % of float
- 14.09%
- 50-day average
- 51.13
- 200-day average
- 31.54
Analyst view
Price target (mean) 62.33 +19.4% upside
Now 52.20
- Target (low)
- 55.00
- Target (mean)
- 62.33
- Target (high)
- 73.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.2875.
Financials — quick view
PLSE Revenue — quarterly 434.00K
PLSE Net income — quarterly -24.66M
PLSE EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.3095 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.31 | -0.36 | -0.05 | -16.13% |
| May 4, 2026 | Mar 31, 2026 | -0.32 | -0.27 | +0.05 | +15.62% |
| Feb 19, 2026 | Dec 31, 2025 | -0.265 | -0.26 | +0.01 | +1.89% |
| Nov 5, 2025 | Sep 30, 2025 | -0.31 | -0.29 | +0.02 | +6.45% |
| Aug 12, 2025 | Jun 30, 2025 | -0.26 | -0.28 | -0.02 | -7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | Oppenheimer | main | Outperform | Outperform |
| Oct 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 23, 2026 | BTIG | init | — | Buy |
| Sep 9, 2026 | Freedom Capital Markets | init | — | Buy |
| Aug 17, 2026 | Needham | init | — | Buy |
| Aug 10, 2026 | Canaccord Genuity | main | Buy | Buy |
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- pulsebiosciences.com
News
Pulse Biosciences to Present at Stifel 2026 Healthcare Conference 
Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026 
Varex Imaging (NASDAQ:VREX) vs. Pulse Biosciences (NASDAQ:PLSE) Head to Head Review 
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center 
Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida 
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center 
Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60 
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026 
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
Your note
Sign in to keep a note on PLSE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRETT BURKE T | Former | Sale | Dec 10, 2024 | 63,172 |
| DANAHY KEVIN PATRICK | Officer | Conversion of Exercise of derivative security | Feb 17, 2026 | 43,298 |
| DUGGAN ROBERT WILLIAM | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 10, 2026 | 49,291,700 |
| LAVIOLETTE PAUL A | Chief Executive Officer | Purchase | May 10, 2026 | 15,846 |
| UECKER DARRIN R | Chief Technology Officer | Conversion of Exercise of derivative security | Sep 16, 2025 | 284,406 |
| ZANGANEH MAHKAM | Director | Conversion of Exercise of derivative security | Feb 2, 2025 | 873,469 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 2.07% | 1,466,702 | 76.56M | Jun 29, 2026 |
| Bank of America Corporation | 2.04% | 1,446,611 | 75.51M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 1.11% | 788,640 | 41.17M | Jun 29, 2026 |
| Portolan Capital Management, LLC | 1.06% | 753,333 | 39.32M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 1.06% | 748,638 | 39.08M | Jun 29, 2026 |
| Balyasny Asset Management LP | 1.01% | 718,103 | 37.48M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.78% | 554,612 | 28.95M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.69% | 485,300 | 25.33M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.69% | 489,643 | 25.56M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 0.49% | 343,542 | 17.93M | Aug 30, 2026 |
| MFS SERIES TRUST I-MFS New Discovery Fund | 0.48% | 339,453 | 17.72M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.30% | 215,880 | 11.27M | Jun 29, 2026 |